ClinicalTrials.Veeva

Menu

Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data

Arbor Research Collaborative for Health logo

Arbor Research Collaborative for Health

Status

Completed

Conditions

IgAN - IgA Nephropathy

Study type

Observational

Funder types

Other

Identifiers

NCT07607002
OAK-ISS-2025-002154

Details and patient eligibility

About

This study leverages the global Dialysis Outcomes and Practice Patterns Study (DOPPS) database to generate real-world evidence on the burden of IgAN in patients who progress to kidney failure and require maintenance hemodialysis (HD). We will first aim to understand prevalence of IgAN in a global cohort of in-center HD patients. The second and third objectives aim to quantify the patient burden of IgAN using a two-step approach: first, a detailed single-arm evaluation of outcomes within the IgAN population; second, a matched comparison to the broader HD population.

Enrollment

70,000 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years at the time of enrollment
  • Receiving in-center HD treatment at a participating dialysis facility
  • Able to provide informed consent, if required by local regulations or ethics boards

Exclusion criteria

-

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems